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The most serious adverse reaction associated with treatment with epidermal growth 21 
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is drug-induced interstitial lung 22 
disease (ILD). Because EGFR-TKIs are key drugs for patients with non-small cell lung 23 
cancer who have somatic activating mutations of the epidermal growth factor receptor 24 
gene (EGFR mutations), several cases of retreatment with EGFR-TKIs after ILD 25 
induced by these drugs have been reported. Here, we present a 68-year-old man with 26 
lung adenocarcinoma and leptomeningeal metastases having an EGFR mutation who 27 
was retreated with erlotinib after erlotinib-induced ILD. He suffered no ILD recurrence 28 
and his leptomeningeal metastases dramatically improved. In addition to the present 29 
case, reports of nine patients who were retreated with EGFR-TKIs after ILD were 30 
found in the literature. Only one patient had recurrence of ILD (although seven were 31 
retreated at a reduced dose of EGFR-TKIs, including the patient with recurrence). In 32 
contrast, three patients had no recurrence of ILD even without dose-reduction. These 33 
reports suggest that dose-reduction plays a limited role in preventing recurrence. Many 34 
patients received corticosteroids during retreatment, but not the one with recurrence of 35 
ILD. This may suggest that corticosteroids can prevent recurrence due to their 36 
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antiinflammatory properties. 37 
 38 
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1. Introduction 43 
 44 
Because patients with non-small cell lung cancer (NSCLC) who have somatic 45 
activating mutations of the epidermal growth factor receptor (EGFR) gene (EGFR 46 
mutations) generally respond to EGFR-tyrosine kinase inhibitors (EGFR-TKIs; 47 
gefitinib or erlotinib) and can achieve long-term progression-free survival, the presence 48 
of EGFR mutations is a very useful marker for facilitating the choice of treatment for 49 
NSCLC [1-7]. Although systemic chemotherapy for leptomeningeal metastasis (LM) 50 
has been thought to play a limited role because of the belief that the brain is a 51 
pharmacologic sanctuary site, several studies have documented the effectiveness of 52 
EGFR-TKIs in the treatment of LM of NSCLC with EGFR mutations [8-10]. 53 
The most common adverse events associated with treatment with EGFR-TKIs are 54 
rash and diarrhea [11, 12]. Although not too frequent, the most serious adverse reaction 55 
is drug-induced interstitial lung disease (ILD) [13-16]. Because EGFR-TKIs are key 56 
drugs for patients with NSCLC having EGFR mutations, several cases of drug 57 
rechallenge after ILD induced by EGFR-TKIs have been reported. Here, we present a 58 
case report of a 68-year-old man with lung adenocarcinoma and LM having an EGFR 59 
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mutation who received erlotinib retreatment after erlotinib-induced ILD. No evidence 60 
of ILD recurrence was seen, and his LM dramatically improved. We also review the 61 
relevant published literature in this topic. 62 
 63 
2. Case presentation 64 
 65 
 A 68-year-old Japanese man with a 40 pack-year history of smoking was diagnosed 66 
with stage IV lung adenocarcinoma (bone metastases). After one cycle of carboplatin 67 
plus pemetrexed as first-line cytotoxic chemotherapy, he suffered fatigue and 68 
electrolyte abnormality (both grade 3) as complications and elected to discontinue 69 
these drugs chemotherapy. EGFR mutational analysis revealed an exon 20 point 70 
mutation (L858R), and he therefore started erlotinib at 150 mg daily. Although he 71 
achieved a partial response (Fig 1A and 1B), he had cough and dyspnea on effort 8 72 
weeks after initiation of erlotinib therapy. Chest computed tomography (CT) showed 73 
bilateral air space consolidations (Fig. 1C). Bronchoalveolar lavage (BAL) fluid 74 
contained no malignant cells and no pulmonary pathogens including bacteria, fungi, 75 
and Pneumocystis were identified. The fraction of lymphocytes in BAL fluid was 76 
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increased to 60%. Therefore, erlotinib-induced ILD (organized pneumonia [OP] 77 
pattern) was strongly suspected. Erlotinib was discontinued and 30 mg daily 78 
prednisolone (PSL) was initiated. Symptoms and bilateral consolidations in the CT 79 
improved, and PSL was gradually tapered to 5 mg (Fig. 1D).  80 
After cessation of erlotinib, he had received no treatment for 6 months because his 81 
lung cancer did not progress and he refused any further treatment. However; after 6 82 
months without treatment, he had headache and impaired consciousness, and his 83 
Eastern Cooperative Oncology Group performance status (ECOG PS) deteriorated to 2. 84 
Cerebrospinal fluid (CSF) testing revealed the presence of malignant cells and he was 85 
diagnosed with LM. He refused any cytotoxic chemotherapy; instead administration of 86 
250 mg daily gefitinib and 4 mg daily betamethasone in addition to whole brain 87 
radiotherapy was initiated. His symptoms and CSF test, however, worsened, and his 88 
ECOG PS deteriorated to 4. The patient requested erlotinib retreatment despite the risk 89 
of ILD, so we initiated administration of 150 mg daily erlotinib together with 4 mg 90 
betamethasone. Soon after initiation of erlotinib, his symptoms dramatically improved 91 
and ECOG PS improved to 1. Both his CSF test and brain magnetic resonance imaging 92 
also improved (Fig. 2). His LM has not worsened for 8 months of erlotinib rechallenge. 93 
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During the period, betamethasone was gradually tapered to zero and ILD recurrence 94 
has not been observed. 95 
 96 
3. Literature review 97 
 98 
 In addition to the present case, a literature search identified a total of nine cases who 99 
received EGFR-TKI retreatment after ILD induced by these drugs (Table 1) [17-24]. 100 
Three received gefitinib after gefitinib-induced ILD [17, 18, 24], 5 were treated with 101 
erlotinib after gefitinib-induced ILD [19-22], and the remaining one (two including the 102 
present case) received erlotinib after erlotinib-induced ILD [23]. Two patients were 103 
Asians and the other reports were also from Asia, but the ethnicity of the patients was 104 
not stated. Six patients were never-smokers and mMany had severe ILD as revealed by 105 
bilateral diffuse ground glass opacities (GGO) on CT. ILD of all patients went into 106 
remission on cessation of EGFR-TKIs and initiation of corticosteroid therapy. Two 107 
patients (cases 2 and 10 in Table 1) could not be given any chemotherapy other than 108 
EGFR-TKIs due to their poor PS. Although the others were fit enough to receive 109 
chemotherapy, they requested EGFR-TKIs again instead. During the EGFR-TKI 110 
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rechallenge, only case 3 suffered recurrence of ILD. Seven patients were retreated with 111 
a lower dose of EGFR-TKIs including case 3 who nonetheless recurred. In contrast, 112 
cases 5, 6, and 10 had no recurrence in spite of receiving 150 mg daily erlotinib. Many 113 
patients were given corticosteroids during EGFR-TKI rechallenge, but not case 3. 114 
However; case 2 also received no corticosteroids but did not recur. 115 
 116 
4. Discussion 117 
 118 
In this article, we presented a case of successful erlotinib rechallenge for LM after 119 
erlotinib-induced ILD and have summarized previous similar reports (Table 1). 120 
Although nine of these ten cases successfully rechallenged with EGFR-TKIs without 121 
the recurrence of ILD, most of the cases that do suffer recurrence might simply not be 122 
reported. Therefore, the risk of ILD should be considered whenever reinitiating 123 
EGFR-TKI treatment after ILD induced by these drugs. Eight of these ten cases could 124 
have received other chemotherapies, but the patients requested EGFR-TKI therapy 125 
again despite their awareness of the risk of ILD. This was permissible because the 126 
efficacy of EGFR-TKIs was predicted from EGFR mutations or previous tumor 127 
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response. Our case (case 10 in Table 1) was not eligible for other chemotherapy due to 128 
his poor PS, and the treatment of choice remained erlotinib or best supportive care. 129 
Several cases in which LM resistant to gefitinib were improved by erlotinib due to its 130 
higher CSF concentration have been reported [25-27] and ILD with an OP pattern on 131 
CT seems to be associated with good prognosis [28]. Therefore, we used 150 mg daily 132 
erlotinib because of its expected clinical benefit and efficacy despite the risk of ILD.  133 
Seven patients were retreated with lower doses of EGFR-TKIs. Three received a 134 
lower dose of erlotinib after gefitinib-induced ILD. However, the area under the curve 135 
(AUC) of serum concentration of erlotinib at the approved dose (150 mg daily) is 7 136 
times larger than gefitiinib at the approved dose (250 mg daily) [29]. Therefore, in 137 
spite of dose-reduction, higher AUC could be achieved by erlotinib than gefitinib in 138 
these patients. In addition, case 3 had recurrence of ILD despite dose-reduction, and 139 
three cases (cases 4, 5, and 10) had no recurrence of ILD although they received 150 140 
mg daily erlotinib. From these findings, we speculate that blockade of the EGFR 141 
signaling pathway by EGFR-TKIs is not necessarily associated with the occurence of 142 
ILD and that EGFR-TKI dose-reduction plays only a limited role in preventing 143 
recurrence.  144 
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Dallas et al. have reported a similar case of successful erlotinib rechallenge after 145 
erlotinib-induced ILD (case 9). As with the case reported here, that patient had also 146 
received erlotinib retreatment together with corticosteroid after erlotinib-induced ILD. 147 
Many cases were also given corticosteroids together with the EGFR-TKIs, resulting in 148 
clinical benefit. In contrast, case 3 had recurrence of ILD without administration of 149 
corticosteroid. This is consistent with the general use of corticosteroids for treating 150 
drug-induced ILD [30, 31]. Thus, corticosteroid can prevent the recurrence of ILD, 151 
probably because of its antiinflammatory action. 152 
Six patients were never-smokers and CT finding of many patients revealed bilateral 153 
diffuse GGO. We can predict the recurrence of ILD from these factors. In fact, a 154 
previous report has shown that smoking status is one of the risk factors for ILD [14]. In 155 
contrast, another report has shown that the incidence of the bilateral GGO pattern on 156 
CT was relatively high and that such patients have high mortality rate [28]. Therefore, 157 
great caution is required when undertaking rechallenge in these patients. 158 
The mechanism responsible for ILD induced by EGFR-TKIs remains unclear and 159 
several instances of successful EGFR-TKI rechallenge after ILD have been reported, as 160 
described above. EGFR-TKIs are key drugs for patients with NSCLC having EGFR 161 
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mutations. Therefore, rechallenge after ILD should be undertaken considering the 162 
balance between risk and benefit. This present case had an EGFR mutation and was not 163 
eligible for other chemotherapy due to his poor PS. Therefore, the treatment of choice 164 
remained erlotinib or best supportive care. Although he recognized the risk of ILD, he 165 
requested erlotinib retreatment, and this was successful. From these findings, we 166 
suggest 3 criteria before deciding on EGFR-TKI rechallenge after ILD; a) The patient 167 
has an EGFR mutation. b) Few other treatment options except EGFR-TKI remain. c) 168 
The patient recognizes the risk of ILD and makes an informed decision to go ahead 169 
with the rechallenge. In order to assess the safety and the risk of this approach, more 170 
similar cases including other ethnicities need to be accumulated and, if ethically 171 
possible, prospective studies in patients who meet these criteria should be 172 
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Figure Legends 310 
 311 
Figure 1. Chest computed tomography (CT) in a 68-year-old man. A: CT scan before 312 
erlotinib treatment showing a mass in the left upper lobe. B, C: CT scan 10 weeks after 313 
initiation of erlotinib treatment showing a decreased mass (B), but visible bilateral air 314 
space consolidations (C). D: Eight weeks after cessation of erlotinib and initiation of 315 
corticosteroid, showing improvement of the bilateral air space consolidations. 316 
 317 
Figure 2. Brain magnetic resonance imaging (MRI). A: Contrast 318 
(gadolinium)-enhanced T1-weighted MRI during gefitinib treatment before erlotinib 319 
rechallenge, revealing leptomeningeal metastases (arrowheads). Patient performance 320 
status (PS) had deteriorated to 4. B: Two weeks after the initiation of erlotinib, showing 321 
improvement of the leptomeningeal metastases. PS also improved to 1. 322 
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Gefitinib 
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Gefitinib 
(250 mg/day) 
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F, female; M, male; EGFR, epidermal growth factor receptor gene; ILD, interstitial lung disease; CT, computed tomography; GGO, ground glass opacity; 
OP, organized pneumonia; PaO2, arterial oxygen pressure; NA, not available; NE, not evaluated.  
a 
The ethnicity of eight cases was not available, but all reports were from Asia. 
b 
Gefitinib was administered every other day due to blepharitis.  
c 
Case 1 had alveolar hemorrhage. 
d 
There was no description of actual PaO2 or oxygen saturation in Cases 2, 4 and 5. But Cases 2 and 5 had severe ILD and Case 4 needed nasal oxygen 
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NA No NA/PR [21] 
6 NA 6 days 
Erlotinib 
(150 mg/day) 
Yes No PR/PR [22] 
7 NA 6 weeks 
Erlotinib 
(100 mg/day) 
Yes No PR/PR [22] 
8 NA 
NA 
(about 6 months) 
Erlotinib 
(75 mg/day) 
Yes → off No PR/PR [23] 
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Yes → off No PR/PR Present case 
ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; SD; stable 
disease; PR, partial response. 
e 
Gefitinib was administered every other day. 
f 
Gefitinib (250 mg daily) was administered for 7 days followed by 2 weeks rest. 
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